跳至主要内容
临床试验/NCT01440673
NCT01440673已完成不适用

Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

Gachon University Gil Medical Center1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
The numbers (and percentages) of patients who experienced complete response

研究概览

简要总结

  • Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting.
  • NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited.
  • We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.

详细描述

123 female patients (ages 21-60) undergoing laparoscopic hysterectomy

  1. 80mg aprepitant
  2. 125mg aprepitant
  3. placebo

Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 0, 1, 2, 24, and 48 h after surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • female laparoscopic hysterectomy isoflurane anesthesia postoperative opioid use

排除标准

  • liver disease neurologic disease active pulmonary disease cardiac arrhythmia allergies to any perioperative medications

研究组 & 干预措施

aprepitant 125mg

Active Comparator

NK1 receptor antagonist

干预措施: Aprepitant (Drug)

Aprepitant 80 mg

Active Comparator

干预措施: Aprepitant (Drug)

结局指标

主要结局

The numbers (and percentages) of patients who experienced complete response

时间窗: 48 hours postoperatively

* The numbers (and percentages) of patients who experienced complete response, i.e. no nausea, retching, vomiting, or need for rescue treatment * required rescue therapy and peak nausea scores * Adverse effects in the three treatment groups

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wol Seon Jung

Associate professor

Gachon University Gil Medical Center

研究点 (1)

Loading locations...

相似试验